Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine to improve and extend people's lives. Our commercial operations, Pharma International, are fully aligned to our global strategy of focusing on our innovative portfolios. To ensure that we are truly focused, we have narrowed down on our priority disease areas for India where we can create most value. Novartis Corporate Centers (NOCCs) are key enablers of Novartis' priorities. We are positioned globally to bring together expert capabilities and talent across functions, to continuously support driving innovation and deliver excellence. The India site is the largest amongst the six centers we have globally and is supporting our purpose of reimagining medicine.

We are committed to championing sustainable livelihoods and empowering communities. Our focus areas are non-communicable diseases, eliminating leprosy and water neutrality.

This division is responsible for advancing our pipeline of investigational medicines, to bring transformative new treatment options to patients with serious diseases. It leads the clinical development of potential new medicines, running large clinical trials and generating evidence that turns molecules to medicines. It has key hubs in Switzerland (Basel), the USA (East Hanover) and India (Hyderabad and Mumbai).